GB201720401D0 - Means and methods to treat torsin related neurologicl diseases - Google Patents

Means and methods to treat torsin related neurologicl diseases

Info

Publication number
GB201720401D0
GB201720401D0 GBGB1720401.7A GB201720401A GB201720401D0 GB 201720401 D0 GB201720401 D0 GB 201720401D0 GB 201720401 A GB201720401 A GB 201720401A GB 201720401 D0 GB201720401 D0 GB 201720401D0
Authority
GB
United Kingdom
Prior art keywords
neurologicl
torsin
diseases
treat
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1720401.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Vlaams Instituut voor Biotechnologie VIB
Original Assignee
Katholieke Universiteit Leuven
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven, Vlaams Instituut voor Biotechnologie VIB filed Critical Katholieke Universiteit Leuven
Priority to GBGB1720401.7A priority Critical patent/GB201720401D0/en
Publication of GB201720401D0 publication Critical patent/GB201720401D0/en
Priority to EP18816009.7A priority patent/EP3720961A1/en
Priority to PCT/EP2018/083784 priority patent/WO2019110728A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03004—Phosphatidate phosphatase (3.1.3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03016—Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
GBGB1720401.7A 2017-12-07 2017-12-07 Means and methods to treat torsin related neurologicl diseases Ceased GB201720401D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB1720401.7A GB201720401D0 (en) 2017-12-07 2017-12-07 Means and methods to treat torsin related neurologicl diseases
EP18816009.7A EP3720961A1 (en) 2017-12-07 2018-12-06 Means and methods to treat torsin related neurological diseases
PCT/EP2018/083784 WO2019110728A1 (en) 2017-12-07 2018-12-06 Means and methods to treat torsin related neurological diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1720401.7A GB201720401D0 (en) 2017-12-07 2017-12-07 Means and methods to treat torsin related neurologicl diseases

Publications (1)

Publication Number Publication Date
GB201720401D0 true GB201720401D0 (en) 2018-01-24

Family

ID=61007310

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1720401.7A Ceased GB201720401D0 (en) 2017-12-07 2017-12-07 Means and methods to treat torsin related neurologicl diseases

Country Status (3)

Country Link
EP (1) EP3720961A1 (en)
GB (1) GB201720401D0 (en)
WO (1) WO2019110728A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2802775C (en) * 2010-06-17 2019-09-24 Vib Vzw Increased protein expression through increased membrane formation
CL2011000273A1 (en) * 2011-02-08 2011-06-17 Univ Pontificia Catolica Chile Use of a phosphatidic acid phosphohydrolase enzyme (pap) inhibitor or combination of inhibitors, in which the inhibitor is d (+) propranolol, and the combination is racemic mixture of propranolol od (+) propranolol together with desipramine, to prepare a Useful medicine in the treatment of cancer.
WO2017211707A1 (en) * 2016-06-06 2017-12-14 Vib Vzw Means and methods to treat dystonia

Also Published As

Publication number Publication date
WO2019110728A1 (en) 2019-06-13
EP3720961A1 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
EP3349783C0 (en) Compositions and methods relating to the treatment of diseases
HK1246179A1 (en) Methods of treating retinal diseases
HK1217439A1 (en) Toxic aldehyde related diseases and treatment
SG11201608077PA (en) Treatment of nafld and nash
ZA201702214B (en) Methods of using interleukin-10 for treating diseases and disorders
IL283799B (en) Compounds and methods of treating rna-mediated diseases
IL249098A0 (en) Methods and compositions for treating allergy and inflammatory diseases
HK1245127A1 (en) Methods and compositions for treating brain diseases
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
HUE062784T2 (en) Indolinone compounds and their use in the treatment of fibrotic diseases
IL277911A (en) Treating ige-mediated allergic diseases
IL259710A (en) Compositions and methods of treatment for mvid and related diseases
IL275517A (en) Methods and combination therapy to treat cancer
IL270011B (en) Therapeutic compounds and methods
EP2964227A4 (en) Treatment and prophylaxis of kidney diseases
HK1243937A1 (en) Methods of treating diseases
GB201617622D0 (en) Means and methods to treat inflammation
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
GB201720401D0 (en) Means and methods to treat torsin related neurologicl diseases
GB201500555D0 (en) Method and device for the treatment of diseases
IL250244B (en) Preventing and treating inflammatory skin diseases
GB201703768D0 (en) Skin treatment methods
GB201703734D0 (en) Skin treatment methods
GB201516303D0 (en) Compositions and methods relating to the treatment of diseases

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)